PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000976912.69182.0b |
| _version_ | 1797281707406131200 |
|---|---|
| author | Catherine M Broome Donald Arnold Caroline Piatek Eun-Ju Lee Hany Zayed Stanford Peng Ismail Simsek |
| author_facet | Catherine M Broome Donald Arnold Caroline Piatek Eun-Ju Lee Hany Zayed Stanford Peng Ismail Simsek |
| author_sort | Catherine M Broome |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:01:20Z |
| format | Article |
| id | doaj.art-ccfda8237f4149559e47963ae167b6e5 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:01:20Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-ccfda8237f4149559e47963ae167b6e52024-03-03T03:24:11ZengWileyHemaSphere2572-92412023-08-017e691820b10.1097/01.HS9.0000976912.69182.0b202308003-02402PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)Catherine M Broome0Donald Arnold1Caroline Piatek2Eun-Ju Lee3Hany Zayed4Stanford Peng5Ismail Simsek61 MedStar Georgetown University Hospital, Washington, United States2 McMaster University, Department of Medicine, Hamilton, Canada3 University of Southern California, Jane Anne Nohl Division of Hematology, Los Angeles, United States4 New York Presbyterian Hospital - Weill Cornell Medicine, Division of Hematology and Medical Oncology, New York, United States5 Alpine Immune Sciences, Inc., Seattle, United States5 Alpine Immune Sciences, Inc., Seattle, United States5 Alpine Immune Sciences, Inc., Seattle, United Stateshttp://journals.lww.com/10.1097/01.HS9.0000976912.69182.0b |
| spellingShingle | Catherine M Broome Donald Arnold Caroline Piatek Eun-Ju Lee Hany Zayed Stanford Peng Ismail Simsek PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) HemaSphere |
| title | PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) |
| title_full | PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) |
| title_fullStr | PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) |
| title_full_unstemmed | PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) |
| title_short | PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) |
| title_sort | pb2554 design of a phase 1b open label study to assess the safety efficacy pharmacokinetics and pharmacodynamics of povetacicept alpn 303 in subjects with autoimmune cytopenias ruby 4 |
| url | http://journals.lww.com/10.1097/01.HS9.0000976912.69182.0b |
| work_keys_str_mv | AT catherinembroome pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 AT donaldarnold pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 AT carolinepiatek pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 AT eunjulee pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 AT hanyzayed pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 AT stanfordpeng pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 AT ismailsimsek pb2554designofaphase1bopenlabelstudytoassessthesafetyefficacypharmacokineticsandpharmacodynamicsofpovetaciceptalpn303insubjectswithautoimmunecytopeniasruby4 |